Promoted Content Promoted Content


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Obicetrapib

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Morningside Ventures

            Deal Size: $196.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing January 14, 2021


            Funding will support initiation and finalization of Phase 3 development of obicetrapib, a potent ApoB and LDL-c lowering small molecule drug, intended for patients not well-controlled on statins.